What it is
SLU-PP-332 is a small-molecule ERR pan-agonist studied as an exercise mimetic in animal models. No established human protocol exists.
Evidence boundary
Preclinical / speculative. The schedule below is an informal research reference, not validated human guidance.
Trial evidence
No verified human trial found. Relevant preclinical context:
- PMID 36988910 — Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
- PMID 37739806 — A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
- PMID 37961903 — Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
- PMID 41850449 — Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.
Preparation and measurement
Reconstitution: 5 mg vial + 3 mL BAC = 1.67 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Research step 1 | 625 mcg | 37.5 U (0.375 mL) | Twice daily | 8.75 mg/week |
| Research step 2 | 1.25 mg | 75 U (0.75 mL) | Twice daily | 17.5 mg/week |
Research step 1
- Dose
- 625 mcg
- Draw / measure
- 37.5 U (0.375 mL)
- Frequency
- Twice daily
- Weekly total
- 8.75 mg/week
Research step 2
- Dose
- 1.25 mg
- Draw / measure
- 75 U (0.75 mL)
- Frequency
- Twice daily
- Weekly total
- 17.5 mg/week
Weekly totals apply only during the active phase. This is a reported schedule, not a validated human regimen.
Titration rules
-
625 mcg twice daily is the initial research step.
-
1.25 mg twice daily is the higher research step.
-
No human escalation sequence is established.
-
Endurance effects in animal studies
-
Mitochondrial biogenesis signals
-
Do not mistake this for human guidance.
-
Limited safety data
Practical rules
- Treat as preclinical.
- Pair with exercise only as a research concept.
- Do not present as human dosing advice.